RESTORE: An RCT to Evaluate the Efficacy of the Revi System

Inclusion Criteria:

1. Signed written informed consent.

2. Subject is at least 21 years old, with no plans to become pregnant during the trial.If of child bearing potential and sexually active, negative pregnancy test and usingacceptable contraception.

3. Subject has been diagnosed with UUI for at least 6 months.

4. Subject experiences a minimum of four (4) leaking episodes associated with urgency,with at least one episode per day for 2 days documented on a voiding diary for 3consecutive days.

5. If used, subject should be on stable dose of antimuscarinics and/or beta-3adrenergic agonists for at least 1 month prior to baseline and agree to remain onstable medication consumption until the 24-month follow-up visit.

6. If used, subject should be on a stable dose of tricyclic antidepressants, SelectiveSerotonin Reuptake Inhibitors (SSRI) and Serotonin-Norepinephrine ReuptakeInhibitors (SNRI) for at least 3 months prior to baseline.

7. Subject agrees to attend all follow-up evaluations and is willing and capable tocompletely and accurately fill out voiding diaries and questionnaires and is willingto complete required exams and test

Exclusion Criteria:

1. Subject participation in a clinical investigation with an active treatment armwithin the past 90 days.

2. Subject is a high surgical risk with multiple illnesses or active general infectionsthat expose them to excessive bleeding or delayed or non-healing wounds. Thisincludes patients who need anticoagulation therapy that cannot be temporarilystopped for the implantation procedure.

3. Subject with BMI >50.

4. Subject with any metal or other implant within 20cm distance of the area of BlueWindRevi implantation site.

5. Subject variation in diuretics consumption within the last 6 months.

6. Subject has received botulinum toxin injections for OAB within the past 12 months.

7. Subject with previous urinary incontinence surgery or prolapse surgery within thelast 12 months.

8. Subject has had any spinal or genitourinary surgery within the last 6 months.

9. Subject had previous abdominoperineal resection of the rectum or radicalhysterectomy (female)/ prostatectomy (male).

10. Subject with diagnosis of BPH with outflow/obstructive predominant symptoms.

11. Subject has skin, peripheral edema, orthopedic or neurologic anatomical limitationsthat preclude implantation or/and use of the device.

12. Subject with Alzheimer's, Parkinson, MS, stroke (CVI), neuropathy or injuryresulting in neuropathy and/or suspected neurogenic bladder.

13. Subject has recurrent urinary tract infections (3 or more infections in the last 6months), or presence of urinary fistula, or urinary tract obstruction such ascancer, urethral stricture or presence of urinary stone.

14. Subject with history of chemotherapy or pelvic radiotherapy that might have affectedbladder control or caused neuropathies (i.e. peripheral neuropathy).

15. Male subject who have obstructive Benign Prostatic Hyperplasia (BPH) or other lowerurinary tract obstructions.

16. Subject has open wounds or sores on the lower leg or foot or had previous, unhealedtrauma in the implant area or has pitting edema (≥2+) in the lower leg.

17. Subject has Venous or Arterial disease/insufficiency in the lower leg or Vasculitisor dermatologic condition in the lower leg or infections near the implantation sitein the lower leg.

18. Subject has a documented history of allergic response to Platinum iridium, Titanium,Zirconia, Gold, Silicone or Parylene.

19. Subject has other active implantable electronic device/s regardless of whetherstimulation is ON or OFF.

20. Subject has a life expectancy of less than 1 year.